# US Gene Synthesis Market

> US Gene Synthesis Market Research Report: Size, Share, Trend Analysis By Method (Solid-phase Synthesis, Chip-based DNA Synthesis, PCR Based Enzyme Synthesis), by Services (Antibody DNA Synthesis, Viral DNA Synthesis, Others), By Applications (Protein Engineering, Vaccine Design & Development, Disease Diagnosis, Therapeutic Antibodies, Others), By End Users (Biotechnology & Pharmaceutical Companies, Academic & Government Research Institutes, Contract Research Organizations), and by Region (North America, Europe, Asia-Pacific, Rest of the World) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 11.8%
- **2024:** $ 1.9 Million
- **2025:** $ 2.12 Million
- **2035:** $ 6.48 Million
- **Key Players:** Thermo Fisher Scientific (US), Integrated DNA Technologies (US), GenScript (US), Twist Bioscience (US), Eurofins Genomics (US), Synthetic Genomics (US), DNA2.0 (US), LGC Biosearch Technologies (US)

**Report ID:** MRFR/HC/11810-CR · **Pages:** 100 · **Author:** Nidhi Mandole & Garvit Vyas · **Last Updated:** April 02, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-gene-synthesis-market-13335

---

## Market Summary

## US Protein Engineering Market Highlighted Trends & Dynamics

The US gene synthesis market underwent a comprehensive analysis, shedding light on the dynamics of this pivotal segment within the life sciences and biotechnology domain. A meticulous examination of the market reveals key aspects related to its overview, demand patterns, and the share held by companies actively engaged in gene synthesis. Overview: The US gene synthesis market operates within the broader context of life sciences, focusing on the synthesis of genes for various applications, including research, diagnostics, and therapeutic development.

The overview of this market encompasses the methods and technologies employed in gene synthesis, the diversity of applications, and the regulatory landscape that governs this specialized field. Demand: The demand for gene synthesis in the US is intricately linked to the advancements in genomics, biotechnology, and the growing need for custom-designed DNA sequences. Research institutions, biopharmaceutical companies, and academic laboratories are the primary drivers of this demand, seeking reliable and efficient gene synthesis services. The demand is molded by the continuous evolution of genetic research, diagnostic applications, and the pursuit of innovative therapeutic solutions.

Market Analysis: A detailed market analysis delves into the nuances of the US gene synthesis market, scrutinizing the factors that influence its trajectory. This analysis encompasses an examination of the gene synthesis technologies, methodologies, and services offered by companies operating in this space. Understanding the competitive landscape, regulatory considerations, and the impact of technological advancements are integral components of the market analysis, providing stakeholders with a comprehensive view of market dynamics. Company Share: The competitive landscape of the US gene synthesis market unveils the share held by companies actively participating in this sector.

Key players, including but not limited to Twist Bioscience Corporation, GenScript Biotech Corporation, and Integrated DNA Technologies, have emerged as significant contributors to the market. These companies have played a crucial role in shaping the industry, offering a range of gene synthesis services catering to the diverse needs of clients. The analysis of company share involves an assessment of market presence, service portfolios, and strategic initiatives undertaken by these companies.

Understanding the share held by each company provides valuable insights into the competitive dynamics of the gene synthesis market, allowing stakeholders to gauge the influence and market positioning of key industry players. In retrospect, the US gene synthesis market has undergone a comprehensive analysis, offering a detailed view of its overview, demand characteristics, and the company share landscape. This scrutiny is essential for stakeholders, including research institutions, biotechnology companies, and pharmaceutical entities, to make informed decisions and navigate the ever-evolving landscape of gene synthesis.

As genetic research continues to advance, and applications diversify, the market analysis serves as a foundational tool for adapting to the changing needs of clients and the biotechnology industry.

## Market Drivers

### Emergence of Personalized Therapeutics

The US Gene Synthesis Market is increasingly influenced by the emergence of personalized therapeutics. As the healthcare landscape shifts towards individualized treatment approaches, the demand for gene synthesis services is expected to rise. Personalized therapeutics often require specific genetic modifications tailored to the unique genetic makeup of patients. This trend is particularly evident in oncology, where targeted therapies are becoming more prevalent. The market for personalized medicine is projected to reach approximately 3.5 billion USD by 2026, indicating a robust growth trajectory. This shift towards personalized therapeutics is likely to drive further advancements in gene synthesis technologies, enhancing the overall capabilities of the US Gene Synthesis Market.

### Rising Demand for Custom Gene Synthesis

The US Gene Synthesis Market is experiencing a notable increase in demand for custom gene synthesis services. This trend is largely driven by the growing need for tailored genetic solutions in various sectors, including pharmaceuticals and biotechnology. As researchers and companies seek to develop specific genetic constructs for therapeutic applications, the market is projected to expand significantly. According to recent estimates, the market could reach a valuation of over 2 billion USD by 2026, reflecting a compound annual growth rate of approximately 15%. This surge in demand is indicative of the broader shift towards personalized medicine, where customized genetic solutions are becoming essential for effective treatment strategies.

### Advancements in Gene Editing Technologies

The US Gene Synthesis Market is poised for growth due to advancements in gene editing technologies such as CRISPR and TALEN. These innovations have revolutionized the way genes are synthesized and manipulated, allowing for more precise and efficient genetic modifications. As these technologies become more accessible, researchers are increasingly utilizing gene synthesis to create novel genetic constructs for various applications, including gene therapy and agricultural improvements. The integration of these advanced technologies is expected to enhance the capabilities of gene synthesis providers, potentially leading to a market expansion that could exceed 3 billion USD by 2027. This evolution in gene editing is likely to drive further investment and interest in the US Gene Synthesis Market.

### Growing Applications in Synthetic Biology

The US Gene Synthesis Market is witnessing a surge in applications within the field of synthetic biology. This interdisciplinary area combines biology, engineering, and computer science to design and construct new biological parts and systems. As synthetic biology continues to evolve, the demand for gene synthesis services is expected to rise, driven by applications in healthcare, agriculture, and environmental sustainability. The market for synthetic biology is projected to grow significantly, with estimates indicating a potential market size of over 4 billion USD by 2025. This growth is likely to create new opportunities for gene synthesis providers, as they play a crucial role in enabling the development of innovative synthetic biological solutions.

### Increased Investment in Biotechnology Research

The US Gene Synthesis Market is benefiting from increased investment in biotechnology research and development. Government funding, along with private sector investments, is fueling innovation in genetic research, which in turn drives demand for gene synthesis services. The National Institutes of Health (NIH) and other funding bodies have allocated substantial resources to support genetic research initiatives, which are expected to grow in the coming years. This influx of capital is likely to enhance the capabilities of gene synthesis companies, enabling them to offer more advanced and diverse services. As a result, the market is projected to grow steadily, with estimates suggesting a potential market size of around 2.5 billion USD by 2028.

## Future Outlook

The US [Gene Synthesis Market](https://www.marketresearchfuture.com/reports/gene-synthesis-market-11624) is projected to grow at an 11.8% CAGR from 2025 to 2035, driven by advancements in synthetic biology, personalized medicine, and biopharmaceutical innovations.

**New opportunities:**

- Development of customizable gene synthesis platforms for niche applications. Expansion into emerging markets with tailored gene synthesis solutions. Strategic partnerships with biotech firms for co-development of novel therapies.

By 2035, the US Gene Synthesis Market is poised for robust growth, reflecting its critical role in biotechnology advancements.

## Segment Insights

### By Application: Synthetic Biology (Largest) vs. Therapeutics (Fastest-Growing)

The market share distribution in the US gene synthesis market reveals that synthetic biology is the largest segment, driven by its wide-ranging applications across various fields, including biotech research and industrial processes. Therapeutics is rapidly gaining traction, expanding its share as innovations in gene therapy and personalized medicine continue to evolve. The increasing reliance on genetic manipulation technologies also contributes to the overall growth of these segments, underscoring their importance in the marketplace.

Growth trends indicate a robust expansion in the US gene synthesis market, particularly for therapeutics, which is emerging as the fastest-growing segment. This growth is fueled by advancements in CRISPR technology, increased investment in research and development, and a rising demand for customized genetic solutions. Agricultural biotechnology continues to gain momentum as sustainability becomes a priority, while vaccines are bolstered by the need for rapid responses to global health challenges. The synergy among these segments is expected to drive further innovation and market development.

Synthetic Biology: Synthetic Biology (Dominant) vs. Agricultural Biotechnology (Emerging)

Synthetic biology is regarded as the dominant segment due to its foundational role in various biotechnological applications, enabling innovations in gene editing, metabolic engineering, and synthetic genome construction. It encompasses a broad array of applications, including drug development and biofuels, positioning itself as an integral part of modern biotechnology. Conversely, agricultural biotechnology is viewed as an emerging segment, targeting enhancements in crop yield and resistance to pests through genetic modifications. This sector is gaining importance, particularly with the growing global focus on sustainable agricultural practices. As consumers become increasingly aware of food security and bioproducts that promote eco-friendliness, agricultural biotechnology is poised for significant growth, paving the way for a more resilient food supply.

### By Product Type: Oligonucleotides (Largest) vs. Gene Fragments (Fastest-Growing)

In the US gene synthesis market, the product type segment is diverse, with significant contributions from various categories. Oligonucleotides have secured the largest market share, driven by their extensive applications in research and diagnostics. Gene Libraries and Plasmids are also notable, but they hold smaller portions compared to Oligonucleotides. Gene Fragments, while currently at a lower share, are seeing an increasing interest due to advancements in synthetic biology.

The growth trends within the product type segment indicate a promising trajectory for Gene Fragments as they become central to novel research endeavors. Oligonucleotides are likely to maintain their stronghold thanks to their established presence and demand in areas like therapeutics and genetic engineering. Innovations in synthesis technologies and increased funding for gene-related research are pivotal drivers for growth in this segment, positioning it well for the foreseeable future.

Oligonucleotides (Dominant) vs. Gene Fragments (Emerging)

Oligonucleotides represent the dominant force in the product type segment of the US gene synthesis market, favored for their versatility and applicability across various fields, including molecular biology, genomics, and diagnostics. Their robustness in commercial applications underpins their market dominance. In contrast, Gene Fragments are emerging as a vital segment, gaining traction due to rising interest in gene-editing technologies and personalized medicine. While they currently occupy a smaller market share, the increasing focus on synthetic biology is expected to bolster their position, creating opportunities for innovative applications. The distinct characteristics of each segment cater to different needs within the market, fostering a dynamic environment for growth.

### By Technology: DNA Sequencing (Largest) vs. Polymerase Chain Reaction (Fastest-Growing)

DNA Sequencing holds the largest share in the segment of the US gene synthesis market, as it continues to be a critical tool in genomic research and applications. Its robust capabilities enable precise and extensive analysis of genetic material, making it indispensable in various fields such as personalized medicine, diagnostics, and genetic engineering. Following closely, the Polymerase Chain Reaction (PCR) technology is witnessing rapid growth due to its essential role in amplifying DNA, which is crucial for numerous applications like disease detection and genetic testing.

The growth trends in the Technology segment are largely driven by advancements in sequencing technologies and the increasing demand for genetic analysis in research and clinical applications. Moreover, the need for rapid and accurate diagnostic tools, particularly in the wake of global health challenges, is propelling the adoption of PCR. As researchers and healthcare providers prioritize efficiency and precision, these technologies are expected to thrive, with the PCR segment emerging as the fastest-growing area due to its versatility and rapid innovation.

Technology: DNA Sequencing (Dominant) vs. Polymerase Chain Reaction (Emerging)

DNA Sequencing is recognized as the dominant force within the Technology segment of the US gene synthesis market. Its ability to provide detailed insights into genetic structures positions it as a preferred choice for researchers. On the other hand, Polymerase Chain Reaction (PCR) stands out as an emerging technology that is experiencing significant growth. PCR is favored for its efficiency in amplifying specific DNA sequences, making it vital for various applications, including medical diagnostics and forensic analysis. While DNA Sequencing is essential for comprehensive genetic studies, PCR's rapid turnaround and adaptability in diverse scenarios contribute to its rising popularity as a transformative tool in genetic analysis.

### By End Use: Academic Research (Largest) vs. Pharmaceutical Companies (Fastest-Growing)

In the US gene synthesis market, the segment distribution shows that Academic Research is the largest end-user, commanding a significant share due to the ongoing demand for synthetic genes in various research applications. Following closely, Pharmaceutical Companies are experiencing rapid growth, leveraging gene synthesis for drug development and therapeutic interventions, indicating a strong shift towards personalized medicine and biotechnology innovation.

The growth trends within these segments are largely driven by advancements in genetic research, increased funding for biotechnology initiatives, and a rise in collaborations between academic institutions and pharmaceutical companies. The growing interest in gene therapies and molecular diagnostics is fueling demand, particularly within pharmaceutical firms, while academic research continues to push the boundaries of genetic knowledge and applications.

Academic Research (Dominant) vs. Pharmaceutical Companies (Emerging)

The Academic Research segment remains the dominant force within the US gene synthesis market, driven by extensive funding from both government and private sectors for innovative research in genetics and genomics. Academic institutions leverage gene synthesis for a wide range of studies, including gene function analysis and development of synthetic biology applications. Conversely, Pharmaceutical Companies, characterized as an emerging segment, are witnessing rapid growth through the integration of gene synthesis in drug discovery and development processes. They are increasingly focused on utilizing synthesized genes for creating novel therapeutics, thus representing a significant trend towards personalized healthcare solutions, position them strategically within the evolving landscape of the biotechnology sector.

## Competitive Benchmarking

The [gene synthesis market](https://www.marketresearchfuture.com/reports/gene-synthesis-market-11624) is characterized by a dynamic competitive landscape, driven by advancements in biotechnology and increasing demand for synthetic genes across various applications, including pharmaceuticals, agriculture, and industrial biotechnology. Key players such as Thermo Fisher Scientific (US), Integrated DNA Technologies (US), and Twist Bioscience (US) are at the forefront, leveraging their technological capabilities and extensive product portfolios to capture market share. These companies focus on innovation and strategic partnerships to enhance their service offerings and expand their market presence, thereby shaping a competitive environment that is both collaborative and competitive. In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and reduce lead times. The market structure appears moderately fragmented, with several players vying for dominance. However, the collective influence of major companies like GenScript (CN) and Eurofins Genomics (DE) is notable, as they contribute to a competitive atmosphere that encourages innovation and responsiveness to market needs. In October 2025, Thermo Fisher Scientific (US) announced the launch of a new platform designed to streamline gene synthesis workflows, which is expected to significantly reduce turnaround times for customers. This strategic move not only enhances their product offering but also positions the company as a leader in efficiency within the market, potentially attracting a broader customer base seeking rapid solutions. In September 2025, Integrated DNA Technologies (US) expanded its operations by opening a new facility focused on high-throughput gene synthesis. This expansion is strategically important as it allows the company to meet the growing demand for custom DNA products, thereby solidifying its market position and enhancing its capacity to serve large-scale projects. In August 2025, Twist Bioscience (US) entered into a partnership with a leading pharmaceutical company to develop synthetic genes for therapeutic applications. This collaboration underscores the increasing trend of strategic alliances in the market, as companies seek to combine expertise and resources to accelerate product development and innovation. As of November 2025, current competitive trends indicate a strong emphasis on digitalization, sustainability, and the integration of artificial intelligence in gene synthesis processes. Strategic alliances are increasingly shaping the landscape, fostering innovation and collaboration among key players. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on technological advancements, innovative solutions, and reliable supply chains, reflecting the market's shift towards quality and efficiency.

## Report Scope

| MARKET SIZE 2024 | 1.901(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 2.125(USD Million) |
| MARKET SIZE 2035 | 6.484(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 11.8% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Thermo Fisher Scientific (US), Integrated DNA Technologies (US), GenScript (US), Twist Bioscience (US), Eurofins Genomics (US), Synthetic Genomics (US), DNA2.0 (US), LGC Biosearch Technologies (US) |
| Segments Covered | Method, Services, Applications, End Users, Region |
| Key Market Opportunities | Advancements in synthetic biology drive demand for customized gene synthesis solutions in the US Gene Synthesis Market. |
| Key Market Dynamics | Rising demand for personalized medicine drives innovation and competition in the US Gene Synthesis Market. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the projected market valuation for the US gene synthesis market in 2035?**
A: The projected market valuation for the US gene synthesis market in 2035 is $1551.5 Million.

**Q: What was the overall market valuation for the US gene synthesis market in 2024?**
A: The overall market valuation for the US gene synthesis market in 2024 was $732.25 Million.

**Q: What is the expected CAGR for the US gene synthesis market during the forecast period 2025 - 2035?**
A: The expected CAGR for the US gene synthesis market during the forecast period 2025 - 2035 is 7.06%.

**Q: Which companies are considered key players in the US gene synthesis market?**
A: Key players in the US gene synthesis market include Thermo Fisher Scientific, Integrated DNA Technologies, GenScript, Eurofins Genomics, Twist Bioscience, Synthetic Genomics, DNA2.0, Bioneer, and LGC Biosearch Technologies.

**Q: What are the main application segments of the US gene synthesis market?**
A: The main application segments of the US gene synthesis market include Synthetic Biology, Therapeutics, Vaccines, Genetic Engineering, and Agricultural Biotechnology.

**Q: What is the market size for oligonucleotides in the US gene synthesis market?**
A: The market size for oligonucleotides in the US gene synthesis market is projected to grow from $250.0 Million to $500.0 Million.

**Q: How does the market for gene libraries compare to that of plasmids in the US gene synthesis market?**
A: The market for gene libraries is expected to grow from $100.0 Million to $210.0 Million, whereas the market for plasmids is projected to increase from $200.0 Million to $400.0 Million.

**Q: What technology segment is expected to have the highest market size in the US gene synthesis market?**
A: The DNA Sequencing technology segment is expected to have the highest market size, projected to grow from $250.0 Million to $500.0 Million.

**Q: Which end-use segment is anticipated to dominate the US gene synthesis market?**
A: The Biotechnology Companies end-use segment is anticipated to dominate the US gene synthesis market, with a projected growth from $219.9 Million to $460.75 Million.

**Q: What is the expected growth trend for the vaccines application segment in the US gene synthesis market?**
A: The vaccines application segment is expected to grow from $109.35 Million to $230.75 Million, indicating a robust growth trend.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-gene-synthesis-market-13335*